Roth Capital analyst Tony Butler downgraded Forty Seven (FTSV) to Neutral from Buy with a price target of $95.50, up from $55, after the company reached an agreement to be acquired by Gilead Sciences (GILD). The analyst believes Gilead strengthend its immuno-oncology portfolio with the acquisition of Forty Seven's CD47-targeting monoclonal antibody magrolimab.

TD Cowen lowered the firm's price target on Gilead to $85 from $90 and keeps a Buy rating on the shares. The firm said the 5% product sales beat was led by Veklury with an assist from the liver disease franchise and HIV, while legacy HCV cell therapy and Trodelvy partially offset.

RBC Capital lowered the firm's price target on Gilead to $74 from $76 and keeps a Sector Perform rating on the shares. The company's solid quarter, helped by flagship drug Biktarvy in the face of seasonal conerns, may help convince some investors that shares have bottomed out, as its core businesses remain relatively stable and there are more catalysts in the second half of the year, the analyst tells investors in a research note. That said, growth off Gilead's high revenue base remains challenging, especially with medium-term headwinds to HIV, oncology, and CAR-T, the firm added.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Consensus $3.67. Sees FY24 product sales $27.1B-$27.5B.

Reports Q1 revenue $6.7B, consensus $5.92B. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August. New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Oncology portfolio throughout the rest of 2024."